Decrease in circulating iNKT cell activation during regadenoson (RA) infusion into patients with COVID-19. by Joseph Rabin (7399436)

Subjects:

HSP90 inhibition by RGRN-305 decreased the gene expression of proinflammatory cytokines induced by SARS-CoV-2 S protein. by Hakim Ben Abdallah (14578241)

Summary of findings table for the comparison remdesivir 10 days vs. placebo for hospitalized, severe COVID-19. by Alejandro Piscoya (782326)

Subjects:

HSP90 inhibition by RGRN-305 and 17-AAG decreased proinflammatory protein secretion. by Hakim Ben Abdallah (14578241)

Baseline clinical profile of hospitalized COVID-19 patients with low and high renalase. by Basmah Safdar (12213257)

Subjects:

Summary of findings table for the comparison remdesivir 5 days vs. standard of care for hospitalized, moderate COVID-19. by Alejandro Piscoya (782326)

Subjects:

Flowchart of study selection. by Alejandro Piscoya (782326)

Subjects:

Description of characteristics of included studies. by Alejandro Piscoya (782326)

Subjects:

Effect of remdesivir on invasive ventilation at 14 days. by Alejandro Piscoya (782326)

Subjects:

Effect of remdesivir on all-cause mortality at 14 days. by Alejandro Piscoya (782326)

Subjects:

Summary of findings table for the comparison of remdesivir 5 days vs. remdesivir 10 days for hospitalized, severe COVID-19. by Alejandro Piscoya (782326)

Subjects:

Flow chart of study patients from all COVID-19 admissions to the institution from March to July 2020. by Basmah Safdar (12213257)

Subjects:

Evaluation of <i>in vitro</i> activity of LNP-siRNA on LX-2 cells stimulated by 2 ng/mL of TGF-β. by Ying-Chou Chen (263436)

Subjects:

Association of chemotherapy cycles and nausea and vomiting with the decrease of post-treatment vitamin D concentration (n = 136). by Herindita Puspitaningtyas (11618232)

Subjects:

Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants by Fengze Wang (10452968)

“…<p>The neutralizing antibody is a potential therapeutic for the ongoing COVID-19 pandemic. As an antiviral agent, numerous mAbs recognize the epitopes that overlap with ACE2-binding sites in the SARS-CoV-2-RBD. …”

Time adjusted survival curves for high vs. low renalase among patients with COVID-19 disease (using first quartile as cutoff). by Basmah Safdar (12213257)

Subjects:

PGRN decreased Dectin-2 expression on the surface of macrophages and neutrophils. by Jiayu Liu (3951515)

ALDH2 inhibitors decrease stroma-induced ALDH activity in AML cells and sensitize them to chemotherapy. by Bin Yuan (19897)

Cox hazard regression model of renalase and primary composite outcome. by Basmah Safdar (12213257)

Subjects:

Time-adjusted survival curve for IL-6 and renalase among patients with COVID-19 disease (A) For composite outcome^a: High renalase + High IL-6; High renalase + Low IL-6;... by Basmah Safdar (12213257)

Subjects: